Nootropic peptides: thirty compounds, three mechanism families, one honest evidence map.
The neuropeptide research category spans an unusually wide quality range — from Cerebrolysin, which has published Cochrane reviews and large-scale randomised trials in post-stroke populations, to Dihexa, which has not left the rodent lab. This pillar maps thirty compounds across three mechanistic families, assigns each to an evidence tier, and explains exactly where the translation from rodent model or Russian clinical literature to Western regulatory standards holds and where it does not.
- Three mechanism families: ACTH-analog regulatory peptides (Semax, Selank), neurotrophic factor concentrates (Cerebrolysin, Cortexin), and investigational neuroprotective peptides (Dihexa, Davunetide).
- Cerebrolysin has the deepest human evidence in this cluster: Cochrane reviews, EMA registration, multiple RCTs in stroke and Alzheimer's populations.
- Semax and Selank are Russian-registered drugs with genuine clinical literature — but that literature is predominantly Russian-language and has not been independently replicated in Western trial frameworks.
- Dihexa has striking rodent memory data from the University of Washington; no human safety or efficacy data have been published.
- Davunetide is the rare case of a cognitive peptide with a published negative Phase II/III result (PSP trial, 2013).
- This pillar cross-links to the Sleep cluster (Selank's anxiolytic-sleep overlap) and the Longevity cluster (Cerebrolysin's anti-aging adjacent literature).
How this cluster is organised
The thirty spokes group into three mechanistic families, each with a distinct evidential pedigree that shapes how researchers should approach them.
Family 1 — ACTH-analog regulatory peptides. Semax and its acetylated/amidated variants are synthetic analogs of the ACTH(4–10) heptapeptide fragment. They do not carry the full hormonal activity of ACTH but appear to modulate brain-derived neurotrophic factor (BDNF) expression, dopaminergic transmission, and neuroprotection in rodent and Russian clinical models. Selank is a tetrapeptide analog of tuftsin (Thr-Lys-Pro-Arg) with anxiolytic and immunomodulatory properties. Both are registered by the Russian Ministry of Health — Semax since 1995, Selank since 2009 — and have a clinical literature base that is primarily Russian-language.
Family 2 — Neurotrophic factor concentrates. Cerebrolysin is a porcine-brain-derived peptide concentrate — not a single defined molecule but a complex mixture of low-molecular-weight peptides that reportedly mimic neurotrophic factors (BDNF, NGF, CNTF). It is EMA-registered in Austria, Germany, Russia, and several other countries and has the deepest human trial database in the entire cognitive cluster, including published Cochrane-level systematic reviews. Cortexin is a closely related bovine cortex-derived peptide concentrate used primarily in Russian and Eastern European neurology practices.
Family 3 — Investigational neuroprotective peptides. Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) activates the hepatocyte growth factor receptor (MET) and has produced striking results in rodent memory models; no human clinical trials have been published. Davunetide (the NAP octapeptide, NAPVSIPQ) progressed to a Phase II/III trial in progressive supranuclear palsy — providing the rare case of a cognitive peptide with a published negative human trial result. Pinealon is a tripeptide from the Russian "biohacker" circuit with minimal indexed research in Western literature.
Evidence hierarchy across the cluster
The table below assigns each major compound to a translational stage. Stage definitions: (1) In vitro only; (2) Rodent models; (3) Veterinary/primate preclinical; (4) Human Phase I safety; (5) Human Phase II efficacy; (6) Human Phase III or equivalent RCT; (7) Regulatory approval.
| Compound | Best evidence stage | Human RCT? | Key caveat |
|---|---|---|---|
| Cerebrolysin | Stage 6–7 — Phase III RCTs, EMA-registered | Yes | Cochrane reviews rate trial quality moderate; it is a complex peptide mixture, not a single molecule |
| Semax | Stage 5–6 — Russian Phase II–III | Yes (Russian lit) | Not independently replicated in Western RCT framework; primary literature is Russian-language |
| Selank | Stage 5 — Russian Phase II | Yes (Russian lit) | Same evidence-base caveat as Semax |
| Cortexin | Stage 5–6 — Russian Phase III (stroke, TBI) | Yes (Russian lit) | Same caveat; bovine-cortex-derived mixture, not single peptide |
| Davunetide | Stage 6 — Phase II/III (PSP trial) | Yes — negative primary endpoint | PSP trial failed 2013; compelling preclinical tauopathy data but no validated indication |
| Dihexa | Stage 2 — rodent (memory, cognitive decline) | No | Potent MET agonist; no human safety data published; oncogenic risk not characterised |
| Pinealon | Stage 1–2 — in vitro + rodent | No | Minimal Western-indexed research; tripeptide Glu-Asp-Arg from Russian biohacker circuit |
The practical implication: researchers approaching this cluster with translational intent should weight Cerebrolysin evidence most heavily (human RCTs exist, with the caveat of mixture complexity and moderate trial quality ratings). Semax and Selank occupy a genuine intermediate tier — real clinical programmes exist, but they have not cleared the Western replication bar. Dihexa's preclinical data are scientifically compelling but should be read as hypothesis-generating, not as a clinical green light. Our peptides for neuroprotection spoke applies this hierarchy to the question researchers ask most often in this cluster.
The Russian literature problem — stated plainly
Semax has been registered with the Russian Ministry of Health since 1995. Selank received registration in 2009. Both have published Russian-language clinical trial reports, and reviews of this literature exist in English (Kozlovskaya et al., Uspekhi Fiziologicheskikh Nauk 2002; Seredenin & Voronin, Eksperimental'naia i Klinicheskaia Farmakologiia 2009). However, three honest limitations apply:
- Indexing gap. Most primary publications appeared in Russian journals not routinely indexed in PubMed prior to 2010. The literature is real but harder to access and verify than a typical Western trial corpus.
- Methodological detail. Trial methodology descriptions in translated summaries often lack the detail required for Cochrane-style quality assessment — specifically around randomisation concealment, blinding adequacy, and intent-to-treat reporting.
- No Western replication. There is no independent Western replication of the key Semax or Selank efficacy findings. Until that replication exists, the evidence cannot be equated to a Phase III EMA-submission-quality RCT.
The spoke articles, by sub-topic
Semax deep-dive spokes
The Semax research page (spoke 2.1) covers the ACTH(4–10) structural basis, BDNF upregulation mechanism, Russian stroke trial literature, intranasal pharmacokinetics, and Ministry of Health registration. Spoke 2.6 (N-Acetyl Semax Amidate) examines the modified variant marketed as having enhanced stability and CNS penetration; the added evidence base for the modified form is thin. Spoke 2.16 (intranasal Semax dosing methodology) addresses concentration and delivery specifics. Spoke 2.18 (Semax vs modafinil) addresses the most common comparison researchers make when evaluating Semax for focus enhancement. Spoke 2.29 (Semax side effects) aggregates safety signals from the Russian clinical literature.
Selank and the anxiety-focus overlap
The Selank research page (spoke 2.2) maps the tuftsin-analog pharmacology, anxiolytic mechanism (modulation of GABA-A and serotonergic systems), and Russian clinical data for generalised anxiety disorder. Spoke 2.7 (Selank for anxiety) focuses specifically on the anxiety indication. Spoke 2.17 (intranasal Selank dosing) covers concentration and delivery. The cross-cluster bridge to the Sleep pillar — spoke 6.5 in our Sleep cluster covers Selank's sleep effects — reflects genuine mechanistic overlap: Selank's anxiolytic activity has direct sleep-quality implications.
Semax vs Selank: head-to-head
The Semax vs Selank comparison (spoke 2.3) addresses the most common commercial-intent search in this cluster. The compounds share an intranasal delivery route and Russian-registry pedigree but differ substantially in their proposed primary actions: Semax trends toward cognitive enhancement and neuroprotection; Selank trends toward anxiolysis and mood stabilisation. The comparison spoke is honest that both claims rest on Russian clinical evidence that has not been Western-replicated, and evaluates the stacking rationale on mechanistic rather than marketing grounds.
Cerebrolysin deep-dive spokes
The Cerebrolysin research page (spoke 2.5) is the deepest-evidence spoke in the entire Cognitive cluster. Cochrane systematic reviews, multiple large RCTs (ARTEMIDA trial, Guekht et al. Stroke 2017; the CASTA trial series), and EMA registration in several European countries give Cerebrolysin a fundamentally different evidentiary footing from the rest of the cluster. The page is honest that the drug is a complex mixture and that several Cochrane reviews have rated trial quality as moderate. Spoke 2.8 (Cerebrolysin for Alzheimer's) and spoke 3.8 in the Longevity cluster (Cerebrolysin and longevity) provide deeper dives into specific indications.
Dihexa and investigational peptides
Spoke 2.4 covers Dihexa's rodent cognitive-enhancement data and the complete absence of published human data. This is the clearest case in the cluster of a compound where the preclinical rationale is scientifically compelling and the clinical evidence is nonexistent. The hepatocyte growth factor/MET receptor activation mechanism is genuinely novel and not shared by any other compound in this cluster. Spoke 2.9 (Dihexa for brain injury) extends to the traumatic brain injury rationale. Spoke 2.11 (peptides for neuroprotection) serves as the mechanistic hub for the broader neuroprotective class.
Application and comparison spokes
Spokes 2.10 (peptides for focus), 2.15 (best nootropic peptides 2026), 2.19 (peptides for ADHD research), 2.22 (Noopept vs Semax), and 2.23 (peptides for memory) address the practical-application dimension. All are written with explicit evidence grades: where human data exist they are cited; where they do not, the limitation is stated as plainly as this pillar page states it for the cluster as a whole.
Safety and side-effect spokes
Spokes 2.29 (Semax side effects) and 2.30 (Selank side effects) aggregate safety signals from the Russian clinical literature. Our peptide side effects overview provides the central safety hub. Spoke 2.28 (Cerebrolysin cost and access) addresses sourcing in a context where the compound requires import from European pharmacies and is subject to country-specific pharmaceutical regulations.
Cross-cluster bridges
This pillar shares significant mechanistic territory with two adjacent clusters. The Sleep & Circadian pillar shares Selank (spoke 6.5 covers Selank's sleep and anxiolytic overlap with circadian disruption) and shares the GABA-modulation territory. Researchers interested in Selank for cognitive performance should read the sleep spoke as well, because many of the reported cognitive benefits may operate partly through anxiety reduction and sleep quality improvement rather than direct nootropic action.
The Longevity & GH Axis pillar bridges via Cerebrolysin's anti-aging adjacent literature (spoke 3.8 there covers this directly), via Epitalon's reported cognitive correlates (spoke 2.27 in this cluster), and via the broader neuroprotection question that aging researchers pursue in the GH-axis context.
The Weight & Metabolic pillar intersects here via GLP-1's reported effects on cognition — an increasingly discussed topic as post-approval observational data accumulates on cognitive outcomes in semaglutide-treated patients. That bridge runs from this cluster's neuroprotection spokes toward the weight cluster's mechanism discussion rather than the reverse.